Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.42 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5198694 | 1.00 | TACR1 (0.42) | TACR1SLC9A3TAAR1RENSIGMAR1 | |
| SCHEMBL4137188 | 1.00 | TACR1 (0.42) | TACR1SLC9A3TAAR1RENSIGMAR1 | |
| SCHEMBL4126854 | 1.00 | TACR1 (0.42) | TACR1SLC9A3TAAR1RENSIGMAR1 | |
| Hydrochloric Acid SCHEMBL4120835 | 0.99 | TACR1 (0.42) | TACR1SLC9A3TAAR1RENSIGMAR1 | |
| Hydrochloric Acid SCHEMBL4120832 | 0.99 | TACR1 (0.42) | TACR1SLC9A3TAAR1RENSIGMAR1 | |
| Hydrochloric Acid SCHEMBL4127165 | 0.99 | TACR1 (0.42) | TACR1SLC9A3TAAR1RENSIGMAR1 | |
| Hydrochloric Acid SCHEMBL4133667 | 0.99 | TACR1 (0.42) | TACR1SLC9A3TAAR1RENSIGMAR1 | |
| SCHEMBL4132921 | 0.89 | TACR1 (0.41) | TACR1TAAR1RENSLC6A2SLC6A4 | |
| SCHEMBL4132923 | 0.89 | TACR1 (0.41) | TACR1TAAR1RENSLC6A2SLC6A4 | |
| SCHEMBL5227414 | 0.89 | TACR1 (0.42) | TACR1SLC9A3TAAR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465733-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2008-12-16 | — | — | US | claimed |
| EP-1710240-B1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | SERVIER LAB (FR) | 2007-12-05 | — | — | EP | claimed |
| US-20060229318-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-12 | — | — | US | claimed |
| EP-1710240-A1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | Les Laboratoires Servier (FR) | 2006-10-11 | — | — | EP | claimed |
| US-7612061-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20090076030-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-20090075982-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-7465733-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2008-12-16 | — | — | US | disclosed |
| EP-1710240-B1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | SERVIER LAB (FR) | 2007-12-05 | — | — | EP | disclosed |
| US-20060229318-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-12 | — | — | US | disclosed |
| WO-2006106241-A1 | PIPERAZINE DERIVATIVES AND USE THEREOF AS SEROTONIN REUPTAKE INHIBITORS OR AS NEUROKININ ANTAGONISTS | LES LABORATOIRES SERVIER (FR) | 2006-10-12 | — | — | WO | disclosed |
| EP-1710240-A1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | Les Laboratoires Servier (FR) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075982-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | TACR1 45/4885SLC9A3 2096/4885TAAR1 77/4885 |
| US-20090076030-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | TACR1 45/4885SLC9A3 2096/4885TAAR1 77/4885 |
| US-20060229318-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | TACR1 45/4885SLC9A3 2096/4885TAAR1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.